Printer Friendly

ThermoGenesis Releases Enhanced X-MINI CD3 Selection Kit For Researchers.

RANCHO CORDOVA, Calif, April 17, 2019 -- ThermoGenesis Corp., a wholly owned subsidiary of Cesca Therapeutics (NASDAQ: KOOL), announced the release of the enhanced X-MINI CD3 Selection Kit for the research market.

The kit expands on the ability of the original X-MINIkit to select the CD3+ target cells from prepared mononuclear cell samples or from a sample of whole blood.

The kit is the first in a planned product line that will enable the selection of numerous other cell types needed for a variety of applications.

Also included with the release is the X-MINI Pressor accessory, used in conjunction with the X-MINI selection kits to eliminate the X-BACS reagent's buoyancy during the final processing steps.

According to the company, there is an increasing need within the cell-based therapeutics market for cutting-edge tools that improve the manufacturing process, allowing development of the highest-quality therapies, including CAR-T.

The company says it will release additional cell selection kits during 2019, as expansions of its X-BACS product line.

The X-MINI Pressor enables X-MINI kit users to simplify their workflows by improving consistency and decreasing the number of repetitive, manual processing steps required.

The X-MINI Selection Kits leverage the company's proprietary X-BACS platform to provide tangible advantages over traditional cell selection technologies through a unique combination of attributes, including ease of use, high cell recovery and reproducibility and minimal cost.

Both the newly enhanced X-MINI CD3 Selection Kit and X-MINI Pressor are available for purchase.

Contact: http://www.thermogenesis.com

Contact: http://www.cescatherapeutics.com

COPYRIGHT 2019 DataTrends Publications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Company News
Publication:Stem Cell Business News
Date:Apr 29, 2019
Words:249
Previous Article:Hemostemix Announces Convertible Debenture Financing.
Next Article:Stacey Ma Joins Sana As EVP Technical.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters